Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma.

Mettler J, Müller H, Voltin CA, Baues C, Klaeser B, Moccia A, Borchmann P, Engert A, Kuhnert G, Drzezga AE, Dietlein M, Kobe C.

J Nucl Med. 2018 Jun 7. pii: jnumed.118.210047. doi: 10.2967/jnumed.118.210047. [Epub ahead of print]

PMID:
29880508
2.

Falciform Ligament Artery Uptake on 99mTc MAA Planning Scan Before 90Y SIRT Confirmed by Retrospective SPECT/MRI Fusion.

Große Hokamp N, Kobe C, O'Donnell JK, Gupta A.

Clin Nucl Med. 2018 Jul;43(7):522-523. doi: 10.1097/RLU.0000000000002099.

PMID:
29742611
3.

Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?

Boellaard R, Kobe C, Zijlstra JM, Mikhaeel NG, Johnson PWM, Müller S, Dührsen U, Hoekstra OS, Barrington S.

J Nucl Med. 2018 Jul;59(7):1167-1169. doi: 10.2967/jnumed.118.211607. Epub 2018 Apr 6. No abstract available.

PMID:
29626118
4.

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.

Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heukamp L, Sos ML, Heuckmann JM.

Clin Cancer Res. 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001. Epub 2017 Dec 28.

PMID:
29284707
5.

PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma.

Kobe C, Dietlein M, Hellwig D.

Semin Nucl Med. 2018 Jan;48(1):28-36. doi: 10.1053/j.semnuclmed.2017.09.003. Epub 2017 Sep 19. Review.

PMID:
29195615
6.

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.

Stokke C, Gabiña PM, Solný P, Cicone F, Sandström M, Gleisner KS, Chiesa C, Spezi E, Paphiti M, Konijnenberg M, Aldridge M, Tipping J, Wissmeyer M, Brans B, Bacher K, Kobe C, Flux G.

EJNMMI Phys. 2017 Nov 21;4(1):27. doi: 10.1186/s40658-017-0194-3.

7.

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P.

Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10.

PMID:
29133014
8.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.

Lancet. 2018 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.

PMID:
29061295
9.

Orbital Hemangiopericytoma in 68Ga-Prostate-Specific Membrane Antigen-HBED-CC PET/CT.

Hammes J, Kobe C, Hilgenberg U, Lieb WE, Drzezga A.

Clin Nucl Med. 2017 Oct;42(10):812-814. doi: 10.1097/RLU.0000000000001791.

PMID:
28806257
10.

Baseline and longitudinal variability of normal tissue uptake values of [18F]-fluorothymidine-PET images.

Cysouw MCF, Kramer GM, Frings V, De Langen AJ, Wondergem MJ, Kenny LM, Aboagye EO, Kobe C, Wolf J, Hoekstra OS, Boellaard R.

Nucl Med Biol. 2017 Aug;51:18-24. doi: 10.1016/j.nucmedbio.2017.05.002. Epub 2017 May 10.

11.

ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor.

Michels SYF, Scheel AH, Wündisch T, Heuckmann JM, Menon R, Puesken M, Kobe C, Pasternack H, Heydt C, Scheffler M, Fischer R, Schultheis AM, Merkelbach-Bruse S, Heukamp L, Büttner R, Wolf J.

NPJ Precis Oncol. 2017 Mar 20;1(1):4. doi: 10.1038/s41698-017-0004-3. eCollection 2017.

12.

Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.

Dahlem K, Michels G, Kobe C, Bunck AC, Ten Freyhaus H, Pfister R.

Clin Res Cardiol. 2017 Jun;106(6):471-473. doi: 10.1007/s00392-017-1092-3. Epub 2017 Mar 16. No abstract available.

PMID:
28303323
13.

Report of the 6th International Workshop on PET in lymphoma.

Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, Kim WS, Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodéré F, Messiou C, Rahmouni A, Buvat I, Andre M, Hertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montravers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M.

Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017.1298752. Epub 2017 Mar 7.

PMID:
28264597
14.

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.

Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22.

PMID:
28236583
15.

Solitary PSMA-Positive Pulmonary Metastasis in Biochemical Relapse of Prostate Cancer.

Große Hokamp N, Kobe C, Linzenich E, Maintz D, Drzezga A.

Clin Nucl Med. 2017 May;42(5):406-407. doi: 10.1097/RLU.0000000000001582.

PMID:
28195907
16.

Brain Glucose Metabolism in Parry-Romberg Syndrome.

Uhrhan K, Rabenstein M, Kobe C, Drzezga A, Fink GR, Burghaus L.

Clin Nucl Med. 2017 May;42(5):e251-e252. doi: 10.1097/RLU.0000000000001558.

PMID:
28166152
17.

PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer.

Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, Schomäcker K, Heidenreich A, Zlatopolskiy BD, Neumaier B, Drzezga A, Dietlein M.

J Nucl Med. 2017 Jun;58(6):947-952. doi: 10.2967/jnumed.116.185538. Epub 2016 Dec 1.

18.

Polymyalgia rheumatica occurring during treatment with ipilimumab.

Maniu C, Kobe C, Schlaak M, Mauch C, Eming SA.

Eur J Dermatol. 2016 Oct 1;26(5):513-514. No abstract available.

PMID:
27349150
19.

Injuries Associated With Strollers and Carriers Among Children in the United States, 1990 to 2010.

Fowler E, Kobe C, Roberts KJ, Collins CL, McKenzie LB.

Acad Pediatr. 2016 Nov - Dec;16(8):726-733. doi: 10.1016/j.acap.2016.07.002. Epub 2016 Jul 9.

PMID:
27402353
20.

Factors Associated with Age Affect Willingness to Engage in Early End-of-Life Communication Using Electronic Health Record-Tethered Patient Portals.

Bose-Brill S, Kobe C, Kretovics M, Pressler-Vyrda T, Belanger L, Ballenger T, Taylor R.

J Am Geriatr Soc. 2016 Oct;64(10):e88-e90. doi: 10.1111/jgs.14362. Epub 2016 Aug 23. No abstract available.

PMID:
27551955
21.

Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.

Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S.

Clin Cancer Res. 2017 Feb 15;23(4):962-973. doi: 10.1158/1078-0432.CCR-16-0860. Epub 2016 Aug 17.

22.

PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis.

Sickinger MT, von Tresckow B, Kobe C, Borchmann P, Engert A, Skoetz N.

Crit Rev Oncol Hematol. 2016 May;101:86-92. doi: 10.1016/j.critrevonc.2016.03.005. Epub 2016 Mar 6. Review.

PMID:
26971064
23.

Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma.

Kluge R, Chavdarova L, Hoffmann M, Kobe C, Malkowski B, Montravers F, Kurch L, Georgi T, Dietlein M, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Wilson L, Bergstraesser E, Sabri O, Mauz-Körholz C, Körholz D, Hasenclever D.

PLoS One. 2016 Mar 10;11(3):e0149072. doi: 10.1371/journal.pone.0149072. eCollection 2016.

24.

Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, Drzezga A, Wild M.

Mol Imaging Biol. 2016 Jun;18(3):437-45. doi: 10.1007/s11307-016-0942-0.

PMID:
26920354
25.

Developments in oncological positron emission tomography/computed tomography assessment.

Kobe C, Boellaard R, Wolf J, Kuhnert G, Dietlein M, Neumaier B, Drzezga A, Kahraman D.

J Thorac Dis. 2015 Dec;7(12):E637-9. doi: 10.3978/j.issn.2072-1439.2015.12.45. No abstract available.

26.

Erratum to: Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

Kuhnert G, Boellaard R, Sterzer S, Kahraman D, Scheffler M, Wolf J, Dietlein M, Drzezga A, Kobe C.

Eur J Nucl Med Mol Imaging. 2015 Oct 19. [Epub ahead of print] No abstract available.

PMID:
26481912
27.

Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma.

Kobe C, Kuhnert G, Haverkamp H, Fuchs M, Kahraman D, Eich HT, Kriz J, Baues C, Nast-Kolb B, Bröckelmann PJ, Borchmann P, Drzezga A, Engert A, Dietlein M.

Nuklearmedizin. 2015;54(6):241-6. doi: 10.3413/Nukmed-0746-15-06. Epub 2015 Sep 21.

PMID:
26388152
28.

Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group.

Bröckelmann PJ, Goergen H, Fuchs M, Kriz J, Semrau R, Baues C, Kobe C, Behringer K, Eichenauer DA, von Tresckow B, Klimm B, Halbsguth T, Wongso D, Plütschow A, Haverkamp H, Dietlein M, Eich HT, Stein H, Diehl V, Borchmann P, Engert A.

Br J Haematol. 2015 Nov;171(4):547-56. doi: 10.1111/bjh.13646. Epub 2015 Aug 27.

PMID:
26310520
29.

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

Kuhnert G, Boellaard R, Sterzer S, Kahraman D, Scheffler M, Wolf J, Dietlein M, Drzezga A, Kobe C.

Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):249-58. doi: 10.1007/s00259-015-3165-8. Epub 2015 Aug 18. Erratum in: Eur J Nucl Med Mol Imaging. 2015 Oct 19;:.

PMID:
26280981
30.

Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis.

Kobe C, Maintz D, Fischer T, Drzezga A, Chang DH.

Clin Nucl Med. 2015 Nov;40(11):897-8. doi: 10.1097/RLU.0000000000000827.

PMID:
26018688
31.

Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B.

Mol Imaging Biol. 2015 Aug;17(4):575-84. doi: 10.1007/s11307-015-0866-0.

32.

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, Büttner R, Wolf J.

J Thorac Oncol. 2015 Jun;10(6):e40-3. doi: 10.1097/JTO.0000000000000503. No abstract available.

33.

Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group.

Kriz J, Reinartz G, Dietlein M, Kobe C, Kuhnert G, Haverkamp H, Haverkamp U, Engenhart-Cabillic R, Herfarth K, Lukas P, Schmidberger H, Staar S, Hegerfeld K, Baues C, Engert A, Eich HT.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):46-53. doi: 10.1016/j.ijrobp.2015.01.048.

PMID:
25863753
34.

Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.

Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N.

Cochrane Database Syst Rev. 2015 Jan 9;1:CD010533. doi: 10.1002/14651858.CD010533.pub2. Review.

PMID:
25572491
35.

Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.

Suleiman AA, Frechen S, Scheffler M, Zander T, Kahraman D, Kobe C, Wolf J, Nogova L, Fuhr U.

J Thorac Oncol. 2015 Jan;10(1):84-92. doi: 10.1097/JTO.0000000000000330.

36.

Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.

Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M.

J Clin Oncol. 2014 Jun 10;32(17):1776-81. doi: 10.1200/JCO.2013.53.2507. Epub 2014 May 5.

PMID:
24799482
37.

Interim PET response criteria in paediatric non-Hodgkin's lymphoma. Results from a retrospective multicenter reading.

Furth C, Erdrich AS, Steffen IG, Ruf J, Stiebler M, Kahraman D, Kobe C, Schönberger S, Grandt R, Hundsdoerfer P, Hauptmann K, Amthauer H, Hautzel H.

Nuklearmedizin. 2013;52(4):148-56. doi: 10.3413/Nukmed-0546-12-12. Epub 2013 Apr 10.

PMID:
23928982
38.

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C.

Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575. Epub 2013 Jul 29.

PMID:
23805904
39.

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.

Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B, Zander T, Nogova L, Scheffler M, Dietlein M, Kobe C, Holstein A, Maintz D, Büttner R, Wolf J.

Lung Cancer. 2013 Jul;81(1):142-3. doi: 10.1016/j.lungcan.2013.02.018. Epub 2013 Apr 1.

PMID:
23558310
40.

Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size.

Meixner M, Hellmich M, Dietlein M, Kobe C, Schicha H, Schmidt M.

Nuklearmedizin. 2013;52(3):71-80. doi: 10.3413/Nukmed-0530-12-09. Epub 2013 Mar 13.

PMID:
23483137
41.

Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Scheffler M, Zander T, Nogova L, Kobe C, Kahraman D, Dietlein M, Papachristou I, Heukamp L, Büttner R, Boellaard R, Lammertsma AA, Querings S, Stoelben E, Engel-Riedel W, Neumaier B, Wolf J.

PLoS One. 2013;8(1):e53081. doi: 10.1371/journal.pone.0053081. Epub 2013 Jan 4.

42.

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, Krause A, Kobe C, Kahraman D, Engert A, Scheid C, Chakupurakal G, Hallek M, von Bergwelt-Baildon M.

J Clin Oncol. 2013 Feb 10;31(5):e59-63. doi: 10.1200/JCO.2012.43.6832. Epub 2012 Dec 26. No abstract available.

PMID:
23269992
43.

Large mediastinal tumor mass as a prognostic factor in Hodgkin's lymphoma. Is the definition on the basis of a chest radiograph in the era of CT obsolete?

Kriz J, Mueller RP, Mueller H, Kuhnert G, Engert A, Kobe C, Haverkamp U, Eich HT.

Strahlenther Onkol. 2012 Nov;188(11):1020-4. doi: 10.1007/s00066-012-0163-7.

PMID:
23053141
44.

Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.

Kahraman D, Holstein A, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Dietlein M, Wolf J, Kobe C.

Clin Nucl Med. 2012 Nov;37(11):1058-64. doi: 10.1097/RLU.0b013e3182639747.

PMID:
23027207
45.

Calcitonin screening in patients with thyroid nodules. Diagnostic value.

Schneider C, Kobe C, Schmidt M, Kahraman D, Malchau G, Faust M, Schicha H, Dietlein M.

Nuklearmedizin. 2012;51(6):228-33. doi: 10.3413/Nukmed-0494-12-04. Epub 2012 Sep 3.

PMID:
22940904
46.

In vitro endothelialization of electrospun terpolymer scaffolds: evaluation of scaffold type and cell source.

Heath DE, Kobe C, Jones D, Moldovan NI, Cooper SL.

Tissue Eng Part A. 2013 Jan;19(1-2):79-90. doi: 10.1089/ten.TEA.2011.0655. Epub 2012 Sep 4.

47.

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.

Scheffler M, Kobe C, Zander T, Nogova L, Kahraman D, Thomas R, Neumaier B, Dietlein M, Wolf J.

Lung Cancer. 2012 Sep;77(3):617-20. doi: 10.1016/j.lungcan.2012.05.110. Epub 2012 Jun 20.

PMID:
22726919
48.

Differentiated thyroid carcinoma: is there any evidence for the use of recombinant human TSH in thyroid hormone-secreting metastasis?

Schneider C, Kahraman D, Kobe C.

J Nucl Med. 2012 Aug;53(8):1329-30; author reply 1330. doi: 10.2967/jnumed.112.105809. Epub 2012 Jun 1. No abstract available.

49.

Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.

Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Dietlein M, Wolf J, Kahraman D.

Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1117-27. doi: 10.1007/s00259-012-2118-8. Epub 2012 Apr 14.

PMID:
22526960
50.

123I-FP-CIT SPECT imaging of the dopaminergic state. Visual assessment of dopaminergic degeneration patterns reflects quantitative 2D operator-dependent and 3D operator-independent techniques.

Kahraman D, Eggers C, Holstein A, Schneider C, Pedrosa DJ, Dietlein M, Kobe C, Timmermann L, Schmidt M.

Nuklearmedizin. 2012;51(6):244-51. doi: 10.3413/Nukmed-0449-11-12. Epub 2012 Apr 24.

PMID:
22526237

Supplemental Content

Support Center